Ann: Imugene completes $35M Placement & Launches c.$30M SPP, page-325

The dilution from the CR placement is 416.7M shares and are currently down 20%, the SPP is currently 20% more.

"SYDNEY, Australia, Friday 18 August 2023: Imugene Limited (ASX:IMU) (Company), a clinical stage immuno-oncology company, is pleased to announce it has received firm commitments from institutional and sophisticated investors for a $35 million placement (Placement Subscribers) of approximately 416.7m new fully paid ordinary shares (New Shares) in the Company at a price of $0.084 per share (Placement).

The Placement is being followed by a share purchase plan (SPP), to raise approximately $30 million, for existing eligible shareholders (Eligible Shareholders) at the lower of $0.084 and a 2.5% discount to the 5-day VWAP up to and including the closing date of the SPP.

Under the Placement and SPP (together, the Offer), Placement Subscribers and Eligible Shareholders are anticipated to receive one free option for every New Share (New Options) subscribed for under the Offer (Options Offer). The New Options will have an exercise price of $0.118 per option with an expiration of 31 August 2026 and will be subject to shareholder approval. It is intended that the New Options will be quoted on the ASX."